In summary, our findings suggest that an imbalanced EC/MSC ratio in BM at day +78 of therapy is associated with a shorter DFS of BCP-ALL patients, independently of their MRD status. The gene discussed is OPN1SW; the disease is acute lymphoblastic leukemia.